COMP <GO>
TMDX vs MDT // EV/EBITDA & P/E VALUATION
TransMedics Group Inc. (NASDAQ) VS. Medtronic plc. (NYSE) • 15-METRIC TALLY: TMDX 7
— MDT 5
▲ EV/EBITDA & P/E VALUATION LEADER: TMDX
LAST: $65.99 (-1.68%) • MKT CAP: $2.33B
valuation
14.6x
LAST: $96.54 (-0.59%) • MKT CAP: $124.22B
valuation
17.4x
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (TMDX VS. MDT)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | TMDX | MDT | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 59.90% | 65.00% | -5.10 | MDT | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 18.10% | 7.80% | +10.30 | TMDX | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | 14.6x | 17.4x | -2.80 | TMDX | /valuation <GO> |
| Free Cash Flow Yield | 5.74% | 4.37% | +1.37 | TMDX | /fcf-yield <GO> |
| Operating Margin | 17.90% | 17.80% | +0.10 | TMDX | /operating-margins <GO> |
| Net Profit Margin | 31.40% | 0.00% | +31.40 | TMDX | /net-margins <GO> |
| Revenue Growth (YoY) | 37.10% | 8.40% | +28.70 | TMDX | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.93% | -2.93 | MDT | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 3.50 | 3.08 | +0.42 | TMDX | /balance-sheet <GO> |
| Piotroski F-Score Quality | 8/9 | 9/9 | -1.00 | MDT | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 32.5 | 61.8 | -29.30 | MDT | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 0.91 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | 10.2x | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $2.33B | $124.22B | -$121.89B | MDT | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | TMDX REV | MDT REV | TMDX GROSS % | MDT GROSS % | TMDX FCF | MDT FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $605.5M | $36.36B | 59.9% | 65.0% | $133.6M | $5.43B |
| FY 2024 | $441.5M | $33.54B | 59.4% | 65.3% | -$80.9M | $5.18B |
| FY 2023 | $241.6M | $32.36B | — | — | -$13.0M | $5.33B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
TMDX // BETA —
MDT // BETA 0.91